The Cooper Companies, Inc. (COO) Up 7.1% — Time to Capitalize on the Move?
The Cooper Companies, Inc. (COO) surged 7.09% on Friday, adding $4.40 to close at $66.42 on the NASDAQ. The move was decisive and broad-based, reflecting a genuine shift in investor sentiment following a catalyst-driven session. Despite the strong single-day performance, COO still sits roughly 26% below its 52-week high of $89.83, reached on December 5, 2025—leaving meaningful room for recovery if the current momentum carries forward.
Volume came in at approximately 2.05 million shares, running just below the 90-day average of roughly 2.20 million. The near-average turnover tells a straightforward story: participation was healthy but not frenzied, suggesting conviction behind the move rather than a short-term squeeze or headline-chasing spike.
Why The Cooper Companies, Inc. Price is Moving Higher
The catalyst was unambiguous. CooperCompanies reported Q2 FY2026 results that cleared the bar on both the top and bottom lines, triggering an immediate repricing. Revenue came in at $1.024 billion, up 6% year over year and 3% organically, while non-GAAP diluted EPS hit $1.10—a 20% increase from the prior-year period. GAAP diluted EPS of $0.66 rounded out a quarter that demonstrated the company's ability to grow earnings faster than revenue, a margin-expansion signal that income-oriented investors tend to reward quickly.
What amplified the reaction was the raised full-year FY2026 guidance. Management lifted its revenue outlook to $4.306 billion–$4.346 billion and bumped non-GAAP EPS guidance to $4.58–$4.66, while projecting free cash flow of $600 million–$625 million. That combination—a beat paired with a raised bar—is precisely the setup that drives gap-up moves, as it signals not just that the company performed well in the rearview mirror, but that execution is expected to remain strong through the remainder of the fiscal year. Both CooperVision and CooperSurgical contributed to the growth story, reinforcing that the lift was structural rather than isolated to a single segment.
Longer-term growth initiatives also add texture to the bullish case, even if they weren't the immediate trigger for Friday's session. CooperCompanies launched MiSight 1 day in Japan on February 10, 2026—the first soft contact lens approved in that market for myopia control—opening a new commercial runway in a high-density, vision-care-focused population. As that product ramps, it provides a durable incremental growth lever beyond the quarterly cadence that drove today's move.
What is the The Cooper Companies, Inc. Rating - Should I Buy?
Weiss Ratings assigns COO a C rating. Current recommendation is Hold.
The sub-index profile is a study in contrasts. Revenue growth of 6.16% and the supporting business fundamentals earn an Excellent Growth Index—a credible designation for a medical device and surgical products company operating across two distinct healthcare end markets with global distribution. The Excellent Solvency Index adds further ballast, indicating that CooperCompanies carries a balance sheet capable of weathering near-term headwinds without the liquidity concerns that shadow more leveraged peers. ROE of 4.87% earns a Good Efficiency Index—a reasonable read for a company still integrating acquisitions and carrying the capital intensity that defines the medical equipment space, though there is clear room for improvement as margins expand.
Where the picture turns more cautious is in the Total Return Index and Volatility Index, both rated Weak. The Total Return signal reflects what the year-to-date chart confirms—COO has spent much of the past year underperforming, sitting more than a quarter below its December 2025 high. The Weak Volatility Index flags that the stock has delivered wide swings in both directions, making position sizing and entry timing more consequential for investors managing risk. A forward P/E of 30.88 isn't extreme for a healthcare equipment name with proven recurring revenue, but it does mean the market has already priced in a degree of execution that management now needs to deliver.
Within the Health Care sector, COO is on equal footing with Intuitive Surgical, Inc. (ISRG, C) and CVS Health Corporation (CVS, C), and a step ahead of both UnitedHealth Group Incorporated (UNH, C-) and Abbott Laboratories (ABT, C-). That relative standing positions CooperCompanies in the middle tier of large-cap Health Care names—neither a standout leader nor a laggard, but a company with improving fundamentals that has yet to fully translate operational progress into sustained shareholder returns.
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) is a Health Care company built around two highly focused commercial platforms that serve distinct but complementary medical markets. CooperVision is one of the world's largest manufacturers of soft contact lenses, offering a comprehensive portfolio spanning daily, monthly, and specialty lenses designed for a wide range of refractive conditions. The division's reach spans more than 100 countries, giving it scale advantages in manufacturing, distribution, and key account relationships with eye care professionals that smaller competitors cannot easily replicate.
CooperSurgical addresses the women's health and fertility markets, supplying medical devices, diagnostics, and fertility-related products used in clinical and surgical settings. Its portfolio includes intrauterine devices, surgical instruments, and a growing range of assisted reproductive technology consumables and services—an area where demographic tailwinds and expanding access to fertility treatments support durable long-term demand. The division's presence across fertility clinics, hospitals, and ob-gyn practices gives it embedded relationships within a highly recurring, professionally driven purchasing cycle.
Across both segments, CooperCompanies benefits from proprietary product platforms, regulatory approvals that create meaningful barriers to entry, and a business model anchored in recurring consumable sales rather than one-time capital equipment purchases. The launch of MiSight 1 day in Japan underscores the company's willingness to pursue first-mover regulatory positioning in large addressable markets, a strategy that builds durable competitive moats over time. That combination of global scale, specialty focus, and recurring revenue architecture supports the operational profile that underpins its investment case.
Investor Outlook
The Cooper Companies, Inc. (COO) carries a Weiss Rating of C (Hold), reflecting a company with genuine operational momentum that has not yet fully converted into sustained stock-price recovery. Investors will be watching whether the raised FY2026 guidance proves conservative or a true floor, and whether the stock can reclaim ground toward its December 2025 high of $89.83 as the margin-expansion story matures. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--